Veracyte, Inc. (VCYT) reported robust first-quarter 2026 financial results, showcasing a 21% year-over-year revenue growth to $139.1 million, driven primarily by its Decipher and Afirma testing franchises. The company performed approximately 47,600 tests, a 17% increase from the previous year, while generating $35.2 million in operating cash flow. Notably, Veracyte raised its fiscal 2026 revenue guidance to between $582 million and $592 million, reflecting a projected growth of 13%-14%, with testing revenue expected to grow by 16%-18%.
This strong performance underscores Veracyte’s operational efficiencies and strategic focus on oncology diagnostics, particularly with the upcoming launches of Prosigna LDT and TruMRD. The company reported a non-GAAP gross margin of 75.7%, attributed to an improved business mix and operational efficiencies, which bodes well for profitability as it continues to expand its market presence.
For market professionals, Veracyte’s sustained growth and strategic product launches highlight its competitive positioning within the oncology diagnostics space, suggesting potential for continued revenue momentum and market leadership as clinical evidence supporting its offerings expands.
Source: fool.com